M.D. Anderson Cancer Center: Leukemia, Myelogenous, Chronic, BCR-ABL Positive trials
The registry lists 69 Leukemia, Myelogenous, Chronic, BCR-ABL Positive studies with M.D. Anderson Cancer Center as lead sponsor. 7 are open to participants now and 30 have results posted.
Phase 1 23Phase 2 49Phase 3 2No phase 6(a study in two phases counts in both)
Studies
Open to participants first, then studies with results posted, then the rest; newest registration first within each.
- Phase II Study Assessing the Safety and Efficacy of Dasatinib in Combination With Ropeginterferon in Patients With Newly Diagnosed Chronic Myeloid Leukemia in Chronic PhaseRecruitingNCT07269470Phase 2
- Phase II Study Assessing the Efficacy and Toxicity of Olverembatinib Monotherapy in Patients With Chronic Myeloid Leukemia in Chronic Phase After Failing One Prior Therapy With a Second Generation Tyrosine Kinase Inhibitor or AsciminibRecruitingNCT06817720Phase 2
- Phase II Study Assessing Efficacy and Safety of Asciminib in Patients With Newly Diagnosed Chronic Myeloid Leukemia in Chronic Phase.RecruitingNCT06236724Phase 2
- Edetate Calcium Disodium or Succimer in Treating Patients With Acute Myeloid Leukemia or Myelodysplastic Syndrome Undergoing ChemotherapyRecruitingNCT03630991Phase 1
- Cladribine, Idarubicin, Cytarabine, and Venetoclax in Treating Patients With Acute Myeloid Leukemia, High-Risk Myelodysplastic Syndrome, or Blastic Phase Chronic Myeloid LeukemiaRecruitingNCT02115295Phase 2
- Ponatinib Hydrochloride as Second Line Therapy in Treating Patients With Chronic Myeloid Leukemia in Chronic Phase Resistant or Intolerant to Imatinib Mesylate, Dasatinib, or NilotinibRecruitingNCT01746836Phase 2
- Chart Review Study of Chronic Myelogenous Leukemia (CML) Patients Treated With Imatinib Outside of a Clinical TrialRecruitingNCT00816114
- Off-the-shelf NK Cells + SCT for Myeloid MalignanciesCompletedNCT05115630Phase 2Results posted
- 2018-0674 - IL-7 for T-Cell Recovery Post Haplo and CB Transplant - Phase I/IICompletedNCT03941769Phase 1/2Results posted
- Venetoclax, Ponatinib, and Dexamethasone in Participants With Philadelphia Chromosome or BCR-ABL Positive Relapsed or Refractory Acute Lymphoblastic Leukemia or Chronic Myelogenous LeukemiaTerminatedNCT03576547Phase 1/2Results posted
- Umbilical Cord Blood Transplant With Added Sugar and Chemotherapy and Radiation Therapy in Treating Patients With Leukemia or LymphomaCompletedNCT03096782Phase 2Results posted
- Bosutinib in Treating Patients With Chronic Myeloid Leukemia in Chronic Phase After Frontline TKI FailureTerminatedNCT02906696Phase 2Results posted
- Phase I/II Study of Bosutinib in Combination With Inotuzumab Ozogamicin in CD22-positive PC Positive ALL and CMLCompletedNCT02311998Phase 1/2Results posted
- Natural Killer Cells Before and After Donor Stem Cell Transplant in Treating Patients With Acute Myeloid Leukemia, Myelodysplastic Syndrome, or Chronic Myelogenous LeukemiaCompletedNCT01904136Phase 1/2Results posted
- Donor Natural Killer Cells and Donor Stem Cell Transplant in Treating Patients With High Risk Myeloid MalignanciesCompletedNCT01823198Phase 1/2Results posted
- Allogeneic Transplantation Using Timed Sequential Busulfan and Fludarabine ConditioningCompletedNCT01572662Phase 2Results posted
- Ponatinib - Frontline for Chronic Myeloid Leukemia (CML) in Accelerated Phase (AP)TerminatedNCT01570868Phase 2Results posted
- An Open-Label, Phase I/II Study of Two Different Schedules of Dasatinib (Sprycel) and Decitabine (Dacogen) Used in Combination for Patients With Accelerated or Blastic Phase Chronic Myelogenous Leukemia (Protocol CA180357)TerminatedNCT01498445Phase 1/2Results posted
- Eltrombopag Olamine in Treating Thrombocytopenia in Patients With Chronic Myeloid Leukemia or Myelofibrosis Receiving Tyrosine Kinase TherapyCompletedNCT01428635Phase 2/3Results posted
- Pegasys in Patients With Chronic Myeloid Leukemia (CML)TerminatedNCT01392170Phase 2Results posted
- Alloreactive Haploidentical Natural Killer (NK) Cells With Busulfan and Fludarabine/ATGCompletedNCT01390402Phase 2Results posted
- Nuvigil in Treatment of Cancer-Related Fatigue in Chronic Myeloid Leukemia PatientsTerminatedNCT01169753Not applicableResults posted
- Ondansetron Versus Aprepitant Plus Ondansetron for EmesisCompletedNCT00954941Phase 2Results posted
- Azacitidine After Allo Blood And Marrow Transplantation (BMT) for Chronic Myelogenous Leukemia (CML)CompletedNCT00813124Phase 2Results posted
- Bendamustine in Acute Leukemia and MDSTerminatedNCT00790855Phase 1/2Results posted
- INCB018424 in Patients With Advanced Hematologic MalignanciesCompletedNCT00674479Phase 2Results posted
- Interleukin 11, Thrombocytopenia, Imatinib in Chronic Myelogenous Leukemia (CML) PatientsCompletedNCT00493181Phase 2Results posted
- Busulfan, Fludarabine, Clofarabine With Allogeneic Stem Cell Transplantation for Acute Myeloid LeukemiaCompletedNCT00469014Phase 2Results posted
- TALL-104 and Gleevec in Chronic Myelogenous Leukemia PatientsTerminatedNCT00415909Phase 2Results posted
- Combination Chemotherapy and Dasatinib in Treating Participants With Philadelphia Positive or BCR-ABL Positive Acute Lymphoblastic Leukemia.CompletedNCT00390793Phase 2Results posted
- Synthetic Vaccine in Patients With Chronic Myeloid Leukemia and Minimal Residual DiseaseCompletedNCT00267085Phase 2Results posted
- Dasatinib in Treating Patients With Early Chronic Phase Chronic Myelogenous LeukemiaCompletedNCT00254423Phase 2Results posted
- Phase II Nilotinib With Newly Diagnosed Chronic Phase Chronic Myelogenous Leukemia (CML)CompletedNCT00129740Phase 2Results posted
- Clofarabine Combinations in Relapsed/Refractory Acute Myeloid Leukemia (AML), Myelodysplastic Syndromes (MDS) and Myeloid Blast Phase Chronic Myeloid Leukemia (CML)CompletedNCT00067028Phase 2Results posted
- Randomized Double Cord Blood Transplant StudyCompletedNCT00067002Phase 2Results posted
- Therapy of HES, PV, Atypical Chronic Myelocytic Leukemia (CML) or Chronic Myelomonocytic Leukemia (CMML), and Mastocytosis With Imatinib MesylateCompletedNCT00038675Not applicableResults posted
- Therapy of Early Chronic Phase CML With Higher-Dose Gleevec, Alpha Interferon, and Low-Dose Ara-CTerminatedNCT00038649Phase 2Results posted
- Fludarabine, Cytarabine, and Pegcrisantaspase for the Treament of Relapsed or Refractory LeukemiaTerminatedNCT04526795Phase 1
- Decitabine, Venetoclax, and Ponatinib for the Treatment of Philadelphia Chromosome-Positive Acute Myeloid Leukemia or Myeloid Blast Phase or Accelerated Phase Chronic Myelogenous LeukemiaCompletedNCT04188405Phase 2
- Cytokine-Treated Veto Cells in Treating Patients With Hematologic Malignancies Following Stem Cell TransplantActive, not recruitingNCT03622788Phase 1/2
- Engineered Donor Stem Cell Transplant in Treating Patients With Hematologic MalignanciesCompletedNCT02960646Phase 1
- Busulfan, Fludarabine Phosphate, and Post-Transplant Cyclophosphamide in Treating Patients With Blood Cancer Undergoing Donor Stem Cell TransplantActive, not recruitingNCT02861417Phase 2
- Axitinib and Bosutinib in Treating Patients With Chronic, Accelerated, or Blastic Phase Chronic Myeloid LeukemiaTerminatedNCT02782403Phase 1
- Dasatinib and Venetoclax in Treating Patients With Philadelphia Chromosome Positive or BCR-ABL1 Positive Early Chronic Phase Chronic Myelogenous LeukemiaActive, not recruitingNCT02689440Phase 2
- An Open-Label, Phase I/II Study of Nilotinib (Tasigna) and MEK-162 (ARRY-162) Used in Combination for Patients With Refractory or Advanced Chronic Myeloid Leukemia and Philadelphia Positive Acute Leukemia (Protocol CAMN107AUS41T)TerminatedNCT02225574Phase 1
- Ruxolitinib in Treating Participants With Chronic Myeloid Leukemia With Minimal Residual Disease While on Therapy With Tyrosine Kinase InhibitorsTerminatedNCT01751425Phase 1
- NK Cells in Cord Blood TransplantationStatus unknownNCT01619761Phase 1
- Azacitidine (AZA) in Minimal Residual Disease (MRD) Chronic Myeloid Leukemia (CML)CompletedNCT01460498Phase 1
- Late Chronic Phase Chronic Myelogenous LeukemiaCompletedNCT01092741Phase 2
- Symptom Burden in Chronic Myeloid Leukemia (CML)Status unknownNCT01046305
- Autologous Transplantation for Chronic Myelogenous LeukemiaCompletedNCT01003054Phase 2
- PR1-Specific Cytotoxic T-Lymphocyte Infusion With Recurrent Chronic Myelogenous Leukemia (CML) After Allogeneic Hematopoietic TransplantationWithdrawnNCT00866346Phase 1
- Autologous Stem Cell Transplants for Chronic Myelogenous LeukemiaWithdrawnNCT00446173Phase 2
- PEG Interferon Alpha 2B and Low-Dose Ara-C in Early Chronic Phase CMLCompletedNCT00303290Phase 1
- PTK 787 and Gleevec in Patients With AML, AMM, and CML-BPCompletedNCT00088231Phase 1/2
- High-Dose Gleevec Alone or in Combination With Peg-Intron and GM-CSF in Early Phase Chronic Myelogenous Leukemia (CML)CompletedNCT00050531Phase 3
- Therapy of Early Chronic Phase CML With GleevecCompletedNCT00048672Phase 2
- Study of Lonafarnib and Gleevec in Chronic Myelogenous LeukemiaCompletedNCT00047502Phase 1
- Zarnestra and Gleevec in Chronic Phase Chronic Myelogenous LeukemiaCompletedNCT00040105Phase 1
- Therapy of Relapsed AML With Chemotherapy and Dendritic Cell Activated LymphocytesWithdrawnNCT00038870Not applicable
- CD8 DLI for Patients With Relapse or Residual Disease Following Allogeneic Stem Cell TransplantationTerminatedNCT00038818Not applicable
- Phase II Study of SCH66336, A Farnesyltransferase Inhibitor in Chronic Myelogenous Leukemia (CML)CompletedNCT00038597Phase 2
- PEG-Intron For Chronic Myelogenous Leukemia Patients Unresponsive To Or Intolerant Of Roferon Or IntronTerminatedNCT00037882Phase 2
- Bortezomib in Treating Patients With Chronic Myelogenous LeukemiaTerminatedNCT00023881Phase 2
- Arsenic Trioxide in Treating Patients With Chronic Phase Chronic Myelogenous Leukemia That Has Not Responded to Previous TreatmentWithdrawnNCT00006091Phase 2
- Dolastatin 10 in Treating Patients With Refractory or Relapsed Acute Leukemia, Myelodysplastic Syndrome, or Chronic Myelogenous LeukemiaCompletedNCT00003693Phase 1
- Chemotherapy and Biological Therapy in Treating Patients With Chronic Phase Chronic Myelogenous LeukemiaCompletedNCT00003239Phase 2
- Peripheral Stem Cell Transplantation Plus Filgrastim in Treating Patients With Acute or Chronic Myelogenous LeukemiaCompletedNCT00002833Phase 2
- Decitabine and Peripheral Stem Cell Transplantation in Treating Patients Who Have Relapsed Following Bone Marrow Transplantation for Leukemia, Myelodysplastic Syndrome, or Chronic Myelogenous LeukemiaCompletedNCT00002832Phase 1/2